Catalyst Pharmaceuticals, Inc.
US ˙ NasdaqCM ˙ US14888U1016

Introduction

This page provides a comprehensive analysis of the known insider trading history of Brian Elsbernd. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Brian Elsbernd has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CPRX / Catalyst Pharmaceuticals, Inc. Chief Compliance/Legal Officer 271,039
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Brian Elsbernd. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CPRX / Catalyst Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CPRX / Catalyst Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CPRX / Catalyst Pharmaceuticals, Inc. Insider Trades
Insider Sales CPRX / Catalyst Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CPRX / Catalyst Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-09-08 CPRX Elsbernd Brian 30,000 20.3000 30,000 20.3000 609,000 2 19.7400 -16,800 -2.76
2025-09-04 CPRX Elsbernd Brian 30,000 19.5200 30,000 19.5200 585,600
2025-09-03 CPRX Elsbernd Brian 20,000 20.0800 20,000 20.0800 401,600
2025-03-03 CPRX Elsbernd Brian 9,720 23.2300 9,720 23.2300 225,796
2025-03-03 CPRX Elsbernd Brian 53,255 22.9300 53,255 22.9300 1,221,137
2024-11-26 CPRX Elsbernd Brian 9,300 21.6500 9,300 21.6500 201,345
2024-11-26 CPRX Elsbernd Brian 3,956 21.5770 3,956 21.5770 85,359
2024-03-27 CPRX Elsbernd Brian 25,000 16.4400 25,000 16.4400 411,000
2023-03-20 CPRX Elsbernd Brian 50,000 16.0690 50,000 16.0690 803,450
2022-11-11 CPRX Elsbernd Brian 14,666 16.2350 14,666 16.2350 238,103

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CPRX / Catalyst Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Brian Elsbernd as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-09-10 2025-09-08 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
S - Sale -30,000 271,039 -9.97 20.30 -609,000 5,502,092
2025-09-10 2025-09-08 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 112,475 301,039 59.65 2.24 251,944 674,327
2025-09-05 2025-09-04 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
S - Sale -30,000 188,564 -13.73 19.52 -585,600 3,680,769
2025-09-05 2025-09-04 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 30,000 218,564 15.91 2.24 67,200 489,583
2025-09-05 2025-09-03 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
S - Sale -20,000 188,564 -9.59 20.08 -401,600 3,786,365
2025-09-05 2025-09-03 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 20,000 208,564 10.61 2.24 44,800 467,183
2025-03-05 2025-03-03 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
S - Sale -53,255 188,564 -22.02 22.93 -1,221,137 4,323,773
2025-03-05 2025-03-03 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 53,255 241,819 28.24 2.24 119,291 541,675
2025-03-05 2025-03-03 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
S - Sale -9,720 188,564 -4.90 23.23 -225,796 4,380,342
2025-03-05 2025-03-03 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 9,270 197,834 4.92 2.24 20,765 443,148
2025-02-19 2025-02-14 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
F - Taxes -2,353 188,564 -1.23
2025-02-19 2025-02-14 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 9,667 190,917 5.33
2024-12-31 2024-12-27 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
F - Taxes -1,941 181,250 -1.06
2024-12-31 2024-12-27 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 6,667 183,191 3.78
2024-12-11 2024-12-09 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
F - Taxes -1,720 176,524 -0.96
2024-12-11 2024-12-09 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 7,067 178,244 4.13
2024-11-29 2024-11-26 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
S - Sale -3,956 171,177 -2.26 21.58 -85,359 3,693,486
2024-11-29 2024-11-26 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 9,756 175,133 5.90 4.01 39,122 702,283
2024-11-29 2024-11-26 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
S - Sale -9,300 165,377 -5.32 21.65 -201,345 3,580,412
2024-11-29 2024-11-26 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 50,244 174,677 40.38 4.01 201,478 700,455
2024-03-28 2024-03-27 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common stock, par value $0.001 per share
S - Sale -25,000 124,433 -16.73 16.44 -411,000 2,045,679
2024-02-16 2024-02-15 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
F - Taxes -2,353 149,433 -1.55
2024-02-16 2024-02-15 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 9,667 151,786 6.80
2023-12-29 2023-12-27 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
F - Taxes -2,623 142,119 -1.81
2023-12-29 2023-12-27 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 6,666 144,742 4.83
2023-03-22 2023-03-20 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
S - Sale -50,000 138,076 -26.58 16.07 -803,450 2,218,743
2023-03-22 2023-03-20 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 50,000 188,076 36.21 1.13 56,500 212,526
2023-02-17 2023-02-15 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
F - Taxes -2,353 138,076 -1.68
2023-02-17 2023-02-15 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 9,666 140,429 7.39
2022-12-08 2022-12-06 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 14,667 130,763 12.63
2022-11-15 2022-11-14 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common stock, par value $0.001 per share
M - Exercise 40,000 116,096 52.57 0.79 31,600 91,716
2022-11-15 2022-11-14 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common stock, par value $0.001 per share
M - Exercise 65,000 76,096 585.80 1.85 120,250 140,778
2022-11-15 2022-11-11 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common stock, par value $0.001 per share
S - Sale -14,666 11,096 -56.93 16.24 -238,103 180,144
2022-02-16 2022-02-14 4 CPRX CATALYST PHARMACEUTICALS, INC.
Restricted Stock Units
A - Award 29,000 950,667 3.15
2021-12-30 2021-12-28 4 CPRX CATALYST PHARMACEUTICALS, INC.
Options to purchase common stock
A - Award 135,000 921,667 17.16
2021-12-06 2021-12-03 4 CPRX CATALYST PHARMACEUTICALS, INC.
Restricted Stock Units
M - Exercise -14,667 786,667 -1.83
2021-12-06 2021-12-03 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
F - Taxes -3,571 25,762 -12.17
2021-12-06 2021-12-03 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common Stock, par value $0.001 per share
M - Exercise 14,667 29,333 100.01
2021-01-04 2020-12-30 4 CPRX CATALYST PHARMACEUTICALS, INC.
Options to purchase common stock
A - Award 200,000 801,334 33.26
2020-12-23 2020-12-22 4 CPRX CATALYST PHARMACEUTICALS, INC.
Restricted Stock Units
A - Award -14,666 601,334 -2.38
2020-12-23 2020-12-22 4 CPRX CATALYST PHARMACEUTICALS, INC.
Common stock, par value $0.001 per share
M - Exercise 14,666 14,666
2019-12-04 2019-12-02 4 CPRX CATALYST PHARMACEUTICALS, INC.
Restricted Stock Units
A - Award 44,000 616,000 7.69
2019-12-04 2019-12-02 4 CPRX CATALYST PHARMACEUTICALS, INC.
Options to purchase common stock
A - Award 132,000 572,000 30.00
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)